Feature | February 04, 2013| Dave Fornell

Game-Changing Technologies to Watch in 2013

My job as editor of DAIC is to help readers keep tabs on the latest in cardiovascular technology and trends. With collaboration from my Editorial Advisory Board, we developed a 2013 editorial calendar based on several predictions on what will be the key game-changing technologies.  These were determined from observations at numerous cardiology meetings we attended and from needs or trends members of the board have seen in their own practices. Here are our top predictions:

• Fractional flow reserve (FFR) is becoming more popular because of sound clinical trial data that continues to be reinforced, its inclusion in treatment guidelines and for its potential to save money by reducing the number of stents implanted. Current iterations of the catheter-based technology can be time-consuming and require use of adenosine, which has limited adoption. A new method called IFR may greatly simplify, reduce time and eliminate the need for adenosine. A second technology showing great promise is computed tomography (CT)–FFR, which measures the FFR for all coronary vessel segments noninvasively and allows placement of virtual stents to measure their hemodynamic impact. 

• Stage 2 meaningful use requirements will greatly impact cardiovascular information systems (CVIS). Stage 2 calls for clinical decision support, which will likely be seen in the form of overlay software to double-check if appropriate use criteria is being followed and to red-flag instances when it is not. Other requirements call for simplified image sharing both inside and outside hospitals, and computerized physician order entry (CPOE). Patient participation is also required, possibly by having them access information or share clinical updates via website interfaces, especially in the case of heart failure and EP implantable device followups.

• New ICD technology with the new subcutaneous ICD systems offer a much simplified implant procedure and the potential to greatly reduce complications.  The results of the MADIT-RIT trial will likely make ICDs more effective by changing the way the devices are programmed. 

• Hemodynamic support devices are seeing a lot of movement with the introduction of a new 5 LPM percutaneous ventricular assist device (PVAD), a new trial examining a PVAD’s impact on infarct size, FDA review of intra-aortic balloon pumps, and the increasing use of mobile extracorporeal membrane oxygenation (ECMO) units, especially in the hybrid OR.

• Near-infrared spectroscopy intravascular imaging may offer a vulnerable plaque detection tool to preemptively stent potential STEMI lesions.  

• Renal denervation therapy has gone from a sideshow session at meetings into the mainstream, with major vendors now making investments. 

Several of these topics are covered in the Jan/Feb 2013 issue of DAIC.

Related Content

Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Overlay Init